Published in Women's Health Weekly, August 1st, 2002
Femprox incorporates alprostadil, a vasodilator, with the NexACT platform drug delivery technology. The results were announced at the 97th annual meeting of the American Urological Association (AUA) in Orlando, Florida.
The multicenter phase II study was a randomized, double-blind, placebo-controlled trial, designed to investigate the efficacy and safety of Femprox cream in 98...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.